Calidi Biotherapeutics’ CLD-201 Secures FDA Fast Track for Innovative Glioblastoma Therapy

Calidi Biotherapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Fast Track designation to its experimental therapy, CLD-201 SuperNova, for the treatment of glioblastoma.…

Continue Reading Calidi Biotherapeutics’ CLD-201 Secures FDA Fast Track for Innovative Glioblastoma Therapy

And the Good News is . . .Cancer Survivors in the United States are Projected to Exceed 22 million people by 2035

Here's a more detailed explanation. The newest American Cancer Society study just released suggests that a diagnosis of cancer is no longer a death sentence. According to a recent U.S.…

Continue Reading And the Good News is . . .Cancer Survivors in the United States are Projected to Exceed 22 million people by 2035
The Ripple Effect of My Colorectal Cancer Journey: How One Small Moment Can Change Your Life
source: pixabay.com

The Ripple Effect of My Colorectal Cancer Journey: How One Small Moment Can Change Your Life

Written by Yla Flores Have you ever experienced a seemingly small moment that ended up changing your life forever? Whether it’s turning left instead of right, going out one night…

Continue Reading The Ripple Effect of My Colorectal Cancer Journey: How One Small Moment Can Change Your Life
Research Breakthrough: Scientists May Have Discovered How Tumor Cells Outwit the Immune System
source: pixabay.com

Research Breakthrough: Scientists May Have Discovered How Tumor Cells Outwit the Immune System

Editor's Note: Chronic conditions and rare diseases don't discriminate, Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have…

Continue Reading Research Breakthrough: Scientists May Have Discovered How Tumor Cells Outwit the Immune System
Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers
source: shutterstock.com

Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers

Carisma Therapeutics, the manufacturer of CT-0508, issued a press release stating that researchers are conducting a combination study using CAR-M cell therapy plus Keytruda (pembrolizumab) in the treatment of overexpressing…

Continue Reading Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers